The case of Heng Zhu, a 35-year-old post-doctoral fellow at Yale University, was the subject of a front-page story in the Jan. 20, 2003, edition of The Wall Street Journal, highlighting visa difficulties that foreign scientists are facing in working in the US in an environment of heightened security in the post-9/11 era. Zhu was forced to return to China when his visa expired in April. Thus far, Zhu has not been able to return to the US despite support from his employer, the report said. Zhu is not alone, as scientists throughout the world are running head-on into US immigration and State Department agencies on heightened states of alert without the resources to match, creating an international logjam that mirrors that of the airport check-in counters, but with consequences that may slow scientific progress at most, and at least, hurt conference and trade show attendance. Previous to this, Zhu was perhaps best known in the microarray community for his work in helping develop 5,800-spot yeast proteome chips.
Werten Bellamy has joined the Detroit law firm of Lewis & Munday to head its corporate and technology division. Bellamy served as chief legal counsel for Celera Genomics Group.
M. Ian Phillips will become vice president of research for the University of South Florida on Jan. 31. He presently directs university’s hypertension center of the college of medicine. Phillips holds a bachelor’s degree in biology and psychology from the University of Exeter (UK), a master’s degree in engineering and science, and a PhD in pharmacology and a DSc degree from the University of Birmingham College of Medicine. His post-doctoral training was at the University of Michigan and at the California Institute of Technology.
Kieran Gallahue, former president of Nanogen, has joined San Diego-based ResMed as president and COO to the Americas, the company said. Gallahue holds a bachelor’s in economics and accounting from Rutgers University and an MBA from Harvard Business School. Gallahue resigned from Nanogen in November.
Gregory Phelps has been named CEO of Ardais of Lexington, Mass. Phelps served as vice chairman of Dyax Corporation. Previously, he was executive vice president of Genzyme; CEO of Viagene; and CEO of Zymogenetics. He is a graduate of Harvard Business School and has a BS from Bradley University.
The White House will name Eric Lander to the National Cancer Advisory Board. Lander, director of the Whitehead Institute/MIT Center for Genome Research, would serve on the board, which oversees the National Cancer Institute and provides peer review for NCI grant applications, for the remainder of a six-year term that expires in March 2006.